MAP2K7 and melanoma: This particular mutation has been implicated in different mechanisms of melanoma progression, for example activation of the downstream MEK/ERK pathway, evasion of senescence and apoptosis, induction of angiogenesis, tissue invasion and metastasis and evasion of the immune surveillance.5 Accordingly, BRAFV600E was identified as a key target for the treatment of V600E-driven melanoma.6